Project Grant R44EB035459
Award Date 9/1/24
Completion Date 8/31/26
Dollars Obligated $1.6M
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Oro Valley, AZ 85704, USA
Similar Awards
- This federal Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $581,723 to The Johns Hopkins University to develop an advanced imaging system called the Alpha-Scope for in vivo 3D autoradiography of radiopharmaceuticals and their radioactive daughter products in small animal studies. The goal is to create a hyperspectral single-photon emission microscope system that can map the microscale distribution of alpha- and beta-emitting...
- The National Cancer Institute (NCI) awarded a $1,003,173 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to Radiopharmaceutical Imaging And Dosimetry, LLC, a company based in Baltimore, Maryland. The funding supports the development of a prototype web/cloud-based quantitative SPECT reconstruction software system for use in clinical trials and ultimately clinical dosimetry for radiopharmaceutical therapy (RPT). The software aims to enable accurate quantitative imaging...
- This $255,730 National Science Foundation project grant supports the development of self-assembling molecular brachytherapy for treatment of metastatic cancer. The goal is to enable radiation therapies for metastatic cancer, which accounts for approximately 90% of cancer deaths in the United States each year. The grantee, Oncurie, LLC, seeks to advance a radiotherapy approach that exploits cancer cells themselves as catalysts for therapeutic delivery. Specifically, the company will develop an...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding of $799,962 to Tripill Biotechnology, Corp. to develop radiolabeled PSMA agents with low salivary gland uptake for improved prostate cancer imaging and therapy. The key products and services to be delivered include: Constructing PSMA derivative compounds, such as NOTA-UNC-PSMA2, that can selectively reduce salivary gland uptake while maintaining high tumor uptake in prostate...
- The National Cancer Institute (NCI) awarded a $696,447 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the Rector & Visitors of the University of Virginia to develop and evaluate a 203Pb/212Pb isotope-based SPECT imaging and targeted alpha therapy as precision therapeutic tools for mesothelioma. The project aims to target a tumor-selective CD46 epitope expressed across all major mesothelioma subtypes using a novel human monoclonal antibody. The research will assess...
- This $149,394 Project Grant was awarded on August 1, 2025 by the National Cancer Institute (NCI), part of the Department of Health and Human Services, under the federal Cancer Detection and Diagnosis Research program (CFDA 93.394). The grant supports research led by the University of California, Davis to advance the development of targeted radiopharmaceuticals for cancer diagnosis and therapy. Specifically, the research focuses on designing, synthesizing, and optimizing novel molecular imaging...
- This Project Grant award from the National Cancer Institute's (CFDA 93.394 - Cancer Detection and Diagnosis Research) will fund a research project titled "Innovative Scan Protocols with Combined Long Axial FOV PET and Spectral CT for Improved Quantification in Oncology". The $666,670 award, effective January 15, 2025, aims to develop advanced imaging protocols and processing techniques that utilize both positron emission tomography (PET) and spectral computed tomography (CT) to enhance...
- This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $399,153 to Alelopharma Inc. to develop an ultra-sensitive molecular diagnostic platform for detecting EML4-ALK gene fusions in non-small cell lung cancer patients. The objective is to create a blood-based "liquid biopsy" test that can accurately identify ALK-positive lesions, which respond well to targeted cancer therapies, without the need for tissue re-biopsy....
- This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $275,000 to M3D, Inc. will develop a novel gamma-ray radiation imager for image-guided tumor diagnostics. The goal is to create a system capable of rapidly and accurately detecting gamma-ray emitting radiotracers used to identify the location of lymph nodes and tumor drainage during cancer surgical procedures. The project will characterize the design parameters of the...
- The National Cancer Institute (NCI) awarded a $400,000 Project Grant under CFDA 93.394 (Cancer Detection and Diagnosis Research) to O2M Technologies LLC to develop a Multifunctional Imager (MFI) that can simultaneously acquire tissue oxygen pressure (pO2) and pH maps using electron paramagnetic resonance imaging (EPRI) techniques. The 12-month project aims to create a 25 MT Halbach-type permanent magnet, new multi-modal transmit-receive electronics, and the integrated MFI instrument. This...